Dapagliflozin Matches Non-Loop Diuretic for AHF Congestion Dapagliflozin Matches Non-Loop Diuretic for AHF Congestion
The SGLT2 inhibitor didn ' t relieve congestion more effectively than a ' thiazide-like ' diuretic when added to furosemide in loop-diuretic –resistant patients with acute heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 6, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
May 12 2023 This Week in Cardiology May 12 2023 This Week in Cardiology
Two new papers on left atrial appendage occlusion, the promise of DNA, statins in the elderly, and SGLT2 inhibitors are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 12, 2023 Category: Transplant Surgery Tags: Cardiology Commentary Source Type: news
FDA Expands Use of Dapagliflozin to Broader Range of HF FDA Expands Use of Dapagliflozin to Broader Range of HF
The SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 9, 2023 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Clues to How SGLT2 Inhibitors Work: CAMEO-DAPA Clues to How SGLT2 Inhibitors Work: CAMEO-DAPA
Ileana Pi ña, MD, MPH, and Barry A. Borlaug, MD, discuss the CAMEO-DAPA study in patients with HFpEF and potential mechanisms of action for SGLT2 inhibitors.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
SGLT2 Inhibitors and Blood Pressure in Heart Failure SGLT2 Inhibitors and Blood Pressure in Heart Failure
Does blood pressure reduction account for the beneficial effects of SGLT2 inhibitors in HFpEF?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Natriuretic Peptides and Potential Treatment Response in HFpEF Natriuretic Peptides and Potential Treatment Response in HFpEF
A new study adds to the evidence that NT-proBNP levels are strong prognostic markers of clinical severity in patients with HFpEF, and may inform potential for treatment response to SGLT2 inhibitors.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 7, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
SGLT2 Inhibitors: Real-World Data Show Benefits Outweigh Risks SGLT2 Inhibitors: Real-World Data Show Benefits Outweigh Risks
Use of an SGLT2 inhibitor was associated with more lower limb amputations and nonvertebral fractures in US patients with CKD and type 2 diabetes receiving routine care, but benefits still outweigh risks.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2023 Category: Cardiology Tags: Nephrology News Source Type: news
Can SGLT2 Inhibitors Limit Acute Kidney Injury in Type 2 Diabetes? Can SGLT2 Inhibitors Limit Acute Kidney Injury in Type 2 Diabetes?
Contrary to the concerns that SGLT2 inhibitors might increase the risk of acute kidney injury when they were first introduced, new data support other findings that this complication is likely not an issue.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 7, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
< 10% of Eligible Type 2 Diabetes Patients Get New but Pricey Drugs < 10% of Eligible Type 2 Diabetes Patients Get New but Pricey Drugs
Data from 1133 US adults with type 2 diabetes show only 9% received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020 despite all of them meeting 2022 criteria for receiving these agents.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 27, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Are High Costs of Newer Diabetes Drugs Deterring Eligible Patients?
(MedPage Today) -- Fewer than 10% of eligible U.S. patients with type 2 diabetes used a GLP-1 receptor agonist or SGLT2 inhibitor, according to nationally representative data.
While it was estimated that 22.4 million U.S. adults with diagnosed... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 27, 2023 Category: Urology & Nephrology Source Type: news
Dapagliflozin Gets Expanded Heart Failure Indication in Europe Dapagliflozin Gets Expanded Heart Failure Indication in Europe
The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 9, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review - van Poelgeest EP, Handoko ML, Muller M, van der Velde N.
PURPOSE: Both heart failure and its treatment with diuretics or SGLT2 inhibitors increase fall risk in older adults. Therefore, decisions to continue or deprescribe diuretics or SGLT2 inhibitors in older heart failure patients who have fallen are generally... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
SGLT2 Inhibitors and the Risk of Pneumonia and Septic Shock SGLT2 Inhibitors and the Risk of Pneumonia and Septic Shock
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes. Could these agents also help lower the risk of pneumonia and septic shock in these patients?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
MARLBOROUGH, Mass.--(BUSINESS WIRE) January 23, 2023 --TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Brenzavvy is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 23, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Type 2 Diabetes Drug Bexagliflozin FDA Approves New Type 2 Diabetes Drug Bexagliflozin
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials that included 5000 patients and more than 300 patients who also had stage 3 chronic kidney disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 23, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
